Immunoglobulin abnormalities are frequent in patients with lupus nephritis

[1] Wijetilleka S(2019)Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review Autoimmun Rev 18 535-541

[2] Mukhtyar C(2018)Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia JAMA Netw Open 1 e184169-S46

[3] Jayne DR(2017)Update on the use of immunoglobulin in human disease: a review of evidence J Allergy Clin Immunol 139 S1-1594

[4] Ala A(2016)EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis Ann Rheum Dis 75 1583-920

[5] Bright P(2011)Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis Ann Rheum Dis 70 909-2313

[6] Chinoy H(2011)BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis Rheumatology 50 2311-1405

[7] Barmettler S(2017)Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis Lupus Sci Med 4 e000229-65

[8] Ong MS(2008)Management of hypogammaglobulinaemia occurring in systemic lupus erythematosus Rheumatology (Oxford) 47 1400-16

[9] Farmer JR(2015)Rituximab-associated hypogammaglobulinaemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease J Autoimmun 57 60-650

[10] Choi H(1997)Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 40 1725-211

[1] Wijetilleka S(2019)Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review Autoimmun Rev 18 535-541

[2] Mukhtyar C(2018)Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia JAMA Netw Open 1 e184169-S46

[3] Jayne DR(2017)Update on the use of immunoglobulin in human disease: a review of evidence J Allergy Clin Immunol 139 S1-1594

[4] Ala A(2016)EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis Ann Rheum Dis 75 1583-920

[5] Bright P(2011)Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis Ann Rheum Dis 70 909-2313

[6] Chinoy H(2011)BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis Rheumatology 50 2311-1405

[7] Barmettler S(2017)Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis Lupus Sci Med 4 e000229-65

[8] Ong MS(2008)Management of hypogammaglobulinaemia occurring in systemic lupus erythematosus Rheumatology (Oxford) 47 1400-16

[9] Farmer JR(2015)Rituximab-associated hypogammaglobulinaemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease J Autoimmun 57 60-650

[10] Choi H(1997)Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 40 1725-211